Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINCH 4: Long Term Extension Study of Filgotinib in Rheumatoid Arthritis
NCT03025308Phase 3Completed
- Sponsor
- Alfasigma
- Start
- Feb 2017
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of filgotinib in rheumatoid arthritis (RA), sponsored by Alfasigma. Started Feb 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03025308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025308.